{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:04:50Z","timestamp":1779771890040,"version":"3.53.1"},"reference-count":28,"publisher":"Universidad del Valle","issue":"4","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["colombiamedica.univalle.edu.co"],"crossmark-restriction":true},"short-container-title":["Colomb Med"],"abstract":"<jats:p>ObjetivoEste estudio examin\u00f3 los factores determinantes de la aceptaci\u00f3n de la vacuna contra la COVID-19 en Colombia, con especial \u00e9nfasis en las respuestas de las personas tras experimentar posibles efectos secundarios.M\u00e9todosSe realiz\u00f3 un estudio transversal mediante un cuestionario an\u00f3nimo en l\u00ednea en Colombia entre enero y marzo de 2023. La encuesta ad hoc recopil\u00f3 informaci\u00f3n sociodemogr\u00e1fica, antecedentes de COVID-19, estado de vacunaci\u00f3n y efectos adversos. Se realizaron an\u00e1lisis descriptivos, pruebas de chi cuadrado y regresi\u00f3n log\u00edstica multinomial (ORa, IC95%) (p &lt;0.05).ResultadosEl 40.2% de los participantes expres\u00f3 dudas o habr\u00eda rechazado la vacunaci\u00f3n si hubiera conocido previamente los posibles efectos secundarios. Las mujeres tuvieron una mayor probabilidad de presentar dudas o de rechazar la vacuna tras experimentar efectos adversos. Los participantes que presentaron efectos secundarios fueron m\u00e1s propensos a cuestionar su decisi\u00f3n de vacunarse. Las personas m\u00e1s j\u00f3venes tuvieron menor probabilidad de desarrollar actitudes negativas tras experimentar efectos secundarios que los adultos mayores. Quienes hab\u00edan recibido solo una dosis presentaron una mayor probabilidad de dudar o rechazar futuras vacunaciones, mientras que quienes hab\u00edan recibido m\u00faltiples dosis presentaron una menor probabilidad de hacerlo. Los participantes que cursaron COVID-19 de manera asintom\u00e1tica tuvieron menor probabilidad de rechazar la vacunaci\u00f3n tras conocer los posibles efectos secundarios, posiblemente porque confiaban m\u00e1s en su sistema inmunol\u00f3gico o ten\u00edan un mayor deseo de proteger a otros.\u00a0ConclusionesLa vacilaci\u00f3n hacia la vacunaci\u00f3n se asoci\u00f3 con el sexo femenino, la presencia previa de efectos adversos y un menor n\u00famero de dosis recibidas, mientras que la menor edad se asoci\u00f3 con una mayor aceptaci\u00f3n. Estos hallazgos resaltan la necesidad de estrategias de comunicaci\u00f3n del riesgo dirigidas a abordar las preocupaciones sobre la seguridad y a fortalecer la confianza en las vacunas.<\/jats:p>","DOI":"10.25100\/cm.v56i4.6609","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T04:35:43Z","timestamp":1778992543000},"page":"e2016609","update-policy":"https:\/\/doi.org\/10.25100\/cm.crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Factores que influyen en la aceptaci\u00f3n de la vacunaci\u00f3n de COVID-19 al conocer los posibles efectos secundarios","Factors influencing COVID-19 vaccination acceptance when knowing potential side effects"],"prefix":"10.25100","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0875-9244","authenticated-orcid":false,"given":"Juan Pablo","family":"\u00c1lvarez Najar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-5464","authenticated-orcid":false,"given":"Isabel","family":"Iguacel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6469-9189","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Mart\u00ednez-Jarreta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6068-1231","authenticated-orcid":false,"given":"Sergio","family":"Couto-Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1204-4356","authenticated-orcid":false,"given":"Ignacio","family":"De Blas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10728","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"106597","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00320-6"},{"key":"106598","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12020176"},{"key":"106599","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.27685"},{"key":"106600","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10050781"},{"key":"106601","unstructured":"5. European Centre for Disease Prevention and Control. COVID-19 vaccination coverage in the EU\/EEA during the 2023-24 season campaigns 1 September 2023 to 31 July 2024. Stockholm: ECDC; 2024. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/covid19-vaccination-coverage-2023-2024.pdf"},{"key":"106602","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.739003"},{"key":"106603","unstructured":"7. Ministerio de Salud y Protecci\u00f3n Social. Vacunaci\u00f3n contra COVID-19. Bogot\u00e1: Ministerio de Salud y Protecci\u00f3n Social; cited 9 nov 2025. Available from: https:\/\/vacunacion.minsalud.gov.co\/EV\/Paginas\/vacunacion-contra-covid-19.aspx"},{"key":"106604","unstructured":"8. World Health Organization. COVID-19 vaccination for indigenous populations in Colombia. Geneva: WHO; 2021. cited 2025 Nov 9. Available from: https:\/\/www.who.int\/about\/accountability\/results\/who-results-report-2020-mtr\/country-story\/2021\/colombia"},{"key":"106605","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9111321"},{"key":"106606","unstructured":"10. Infectious Diseases Society of America. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Arlington: IDSA; 2025. Available from: https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/"},{"key":"106607","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.890517"},{"key":"106608","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckad052"},{"key":"106609","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.40364"},{"key":"106610","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1846397"},{"key":"106611","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2020.100012"},{"key":"106612","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.700014"},{"key":"106613","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071428"},{"key":"106614","doi-asserted-by":"publisher","DOI":"10.18004\/anales\/2023.056.01.25"},{"key":"106615","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.626852"},{"key":"106616","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2021.102059"},{"key":"106617","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.728690"},{"key":"106618","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2025.100767"},{"key":"106619","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2025.105251"},{"key":"106620","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00520-4"},{"key":"106621","doi-asserted-by":"publisher","DOI":"10.1016\/j.econlet.2024.111768"},{"key":"106622","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1059067"},{"key":"106623","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2527327"},{"key":"106624","unstructured":"28. Organisation for Economic Co-operation and Development. Education at a Glance 2021: OECD Indicators. Paris: OECD Publishing; 2021. doi:10.1787\/b35a14e5-en. Available from: https:\/\/www.oecd.org\/en\/publications\/education-at-a-glance-2021_b35a14e5-en.html"}],"container-title":["Colombia Medica"],"original-title":[],"link":[{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/6609\/8442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/6609\/8440","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/6609\/8448","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/6609\/8443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:37:04Z","timestamp":1779770224000},"score":1,"resource":{"primary":{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/view\/6609"}},"subtitle":["Un estudio en Colombia","A study in Colombia"],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,10]]}},"URL":"https:\/\/doi.org\/10.25100\/cm.v56i4.6609","relation":{},"ISSN":["1657-9534","0120-8322"],"issn-type":[{"value":"1657-9534","type":"electronic"},{"value":"0120-8322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"Yes","name":"crosschecked","label":"CrossChecked"},{"value":"Yes","name":"peer_reviewed","label":"Peer Reviewed"},{"value":"2025-12-30","name":"published","label":"Published"}]}}